Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 250

Posts Tagged ‘goldfinch’

The American Society of Nephrology Kidney Week 2019 Annual Meeting

Posted by fidest press agency su venerdì, 8 novembre 2019

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced it will present one oral and two poster presentations at the American Society of Nephrology (ASN) Kidney Week 2019 Annual Meeting, taking place November 5-10, 2019, in Washington, D.C.The oral presentation will address the ways in which Goldfinch Bio’s platform generates induced pluripotent stem cell (iPSC)-derived human podocytes and kidney organoids to enable target validation and preclinical assessment of prospective therapies for kidney disease. The poster presentations will include data on how GFB-887, a sub-type selective, small molecule transient receptor potential canonical 5 (TRPC5) ion channel inhibitor, was effective in reducing proteinuria in animal models of focal segmental glomerulosclerosis (FSGS) and other kidney diseases, as well as data on how Goldfinch Bio’s proprietary Kidney Genome AtlasTM can be leveraged to unravel molecular mechanisms of kidney diseases.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Goldfinch Bio Presents Methods to Mitigate Batch Effects in Whole Genome Sequencing

Posted by fidest press agency su giovedì, 24 ottobre 2019

Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced a novel computational approach applied to its proprietary Kidney Genome Atlas (KGA) to enable a well-calibrated dataset for case-controlled genomic-wide association studies (GWAS) in focal segmental glomerulosclerosis (FSGS). These methods were described in an oral presentation on October 19th at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston, TX.Researchers utilized the KGA, which currently contains whole genome sequencing (WGS) on 23,000 de-identified individual patients, including 2,000 cases of FSGS and other proteinuric disorders, to discover loci associated with FSGS, a disease that causes scarring of the kidney which can lead to kidney failure. The researchers sourced cases and controls from five clinical sites and 21 publicly-available cohort studies. The heterogeneity in sample acquisition presented challenges for downstream analysis, as evidenced by massive inflation in test statistics when standard filtering and quality control methods were applied. Notably, the data revealed a batch effect confounded with case/control status.Researchers then implemented a three-pronged data-driven approach to further determine and control for batch effects: identifying clusters of similar sequencing technologies by conducting a principal component analysis on depth of coverage; implementing a novel use of silhouette scores and permutations to quantify case-control dissimilarity at the dataset-level; and iteratively removing controls with high dissimilarity from cases to achieve a better-calibrated dataset for case-control GWAS.
A preliminary, proof-of-principle analysis in a subset of individuals showed that inflation was well controlled. After confirming the statistical associations, researchers will link the signals to specific genes to identify putative targets for therapeutic intervention.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Goldfinch Bio to Present at Jefferies 2018 Global Healthcare Conference

Posted by fidest press agency su domenica, 3 giugno 2018

Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney disease, today announced that Anthony Johnson, M.D., president and chief executive officer, will present a corporate overview at the Jefferies 2018 Global Health Care Conference in New York on Thursday, June 7, 2018 at 1:30 p.m. Eastern time.
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney diseases. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. http://www.goldfinchbio.com.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

Goldfinch Bio to Present at BioCentury’s Future Leaders in Biotech Industry Conference

Posted by fidest press agency su giovedì, 22 marzo 2018

Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney disease, today announced that Anthony Johnson, M.D., president and chief executive officer, will present a corporate overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference on Friday, March 23, 2018 at 11:30 am Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York City.
Goldfinch Bio is a biotechnology company committed to discover and develop precision medicines for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit http://www.goldfinchbio.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »